Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 18/20 | 0.49 |
| ▸ | MMP3 | P08254 | 13/20 | 0.49 |
| ▸ | MMP1 | P03956 | 11/20 | 0.49 |
| ▸ | MMP7 | P09237 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23833925 | 0.94 | MMP2 (0.46) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL23834136 | 0.94 | MMP2 (0.46) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL23849114 | 0.84 | BIRC2 (0.45) | MMP2MMP3MMP1 | |
| SCHEMBL25508405 | 0.84 | BIRC2 (0.45) | MMP2MMP3MMP1 | |
| SCHEMBL23849177 | 0.82 | MMP2 (0.42) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL25508399 | 0.77 | BIRC2 (0.38) | MMP3MMP1 | |
| SCHEMBL25508328 | 0.77 | BIRC2 (0.38) | MMP3MMP1 | |
| SCHEMBL23834176 | 0.76 | PLA2G2A (0.43) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL23834175 | 0.76 | PLA2G2A (0.43) | MMP2MMP3MMP1MMP7 | |
| SCHEMBL23833842 | 0.76 | PLA2G2A (0.43) | MMP2MMP3MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | ASNS, GLUL, GNMT | MMP2 231/4885MMP3 1450/4885MMP1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.